KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Capital Leases: 2010-2016

Historic Capital Leases for Nektar Therapeutics (NKTR) over the last 7 years, with Dec 2016 value amounting to $2.2 million.

  • Nektar Therapeutics' Capital Leases fell 33.33% to $3.0 million in Q3 2017 from the same period last year, while for Sep 2017 it was $3.0 million, marking a year-over-year decrease of 33.33%. This contributed to the annual value of $2.2 million for FY2016, which is 107.18% up from last year.
  • As of FY2016, Nektar Therapeutics' Capital Leases stood at $2.2 million, which was up 107.18% from $1.1 million recorded in FY2015.
  • Over the past 5 years, Nektar Therapeutics' Capital Leases peaked at $11.6 million during FY2012, and registered a low of $1.1 million during FY2015.
  • In the last 3 years, Nektar Therapeutics' Capital Leases had a median value of $2.2 million in 2016 and averaged $2.5 million.
  • As far as peak fluctuations go, Nektar Therapeutics' Capital Leases slumped by 74.08% in 2015, and later skyrocketed by 107.18% in 2016.
  • Yearly analysis of 5 years shows Nektar Therapeutics' Capital Leases stood at $11.6 million in 2012, then slumped by 30.65% to $8.0 million in 2013, then crashed by 48.58% to $4.1 million in 2014, then tumbled by 74.08% to $1.1 million in 2015, then skyrocketed by 107.18% to $2.2 million in 2016.